register

News & Trends - MedTech & Diagnostics

$6.6 million for Australian research to find answers to critical health questions

Health Industry Hub | September 23, 2019 |

The Morrison Government is investing more than $6.6 million in four research projects that seek to answer important public health questions around melanoma detection in high-risk patients, the effectiveness of breast MRIs, the cost of chronic fatigue and mobile x-rays at residential aged care facilities.

These projects are funded under the Medical Research Future Fund’s (MRFF) $39.8 million Targeted Health System and Community Organisation Research Initiative.

The initiative is designed to address gaps in knowledge and evidence for important health system issues.

This includes the comparative effectiveness of a health service or health system practice.

The focus areas require more targeted research and have high community need but low commercial interest.

This round of funding is focused on targeted research questions and topics, put forward by the National Health Technology Assessment (NHTA) Chairs Committee that seek to examine:

  • The effectiveness of Melanoma Surveillance Photography in high-risk individuals.
  • When breast MRIs improve patient outcomes.
  • The impact of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome on the Australian economy.
  • Whether mobile x-ray units to residents of residential aged care facilities are cost effective.

Research findings will inform improvements in current practice and ultimately support better health outcomes for patients.

You may also like Eye scan sheds new light on Alzheimer’s disease


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.